Group 1: Regulatory Developments - The National Medical Products Administration (NMPA) is seeking public opinion on measures to optimize lifecycle regulation supporting high-end medical device innovation [1] - The draft emphasizes strengthening standards to lead innovation and improving the high-end medical device standard system [1] - Accelerated publication of standards for medical exoskeleton robots and radioactive nuclide imaging devices is planned [1] Group 2: Industry Trends - AI in healthcare is highlighted as a significant innovation direction, enhancing medical device functionality and clinical decision-making [1] - Companies are expected to leverage AI to improve product competitiveness and customer loyalty, solidifying their market position [1] Group 3: Company Performance - MicroPort Robotics (02252) is experiencing strong order trends, with sales contribution from robotics expected to rise from approximately 3% in 2024 to about 40% by 2033 [2] - Yimaitong (02522) is advancing in medical imaging services and has launched an AI company that released a global first full-modal medical imaging model [2] - Yongsheng Medical (01612) reported a revenue of approximately HKD 801 million for 2024, a year-on-year increase of 11.6%, driven by increased orders in imaging disposable products [3] - Kangji Medical (09997) is set to launch its surgical robot business, with significant investments in its subsidiary Weijing Medical, which has completed clinical trials for its four-arm surgical robot system [4]

报名：首届全球眼科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 报名：首届全球骨科大会 | 奖项评选 MedRobot 2025年3月24日， 康基医疗 （09997.HK）发布了2024年年报。康基医疗是国内领先的微创外科手 术器械及配套耗材（MISIA）平台，拥有 "设备+器械+耗材+手术机器人" 四大产品管线，能够提供 微创手术一体化解决方案。 # 财报数据 2024年，公司实现营收 10.09亿 元（同比+8.9%），归母净利润 5.81亿 元（同比 +15.4% ）。 经计算， 公司24H2收入5.50亿元（同比+5.2%），24H2归母净利润2.96亿元（同比+18.9%）。董事会建议派付 2024年末期股息每股股份人民币24分。 公司经营亮点： # 关于 康基医疗 报告期内， 公司于唯精医疗的持股由35%增加至 约41.99% 。2024年3月， 唯精医疗四臂手术机器人 系统已完成多科室人体临床试验 ，并已在报告期内向国家药品监督管理局(NMPA)提交注册申请。预计 将于2025年第二季度获得监管部门批准。 报告期内，公司国内收入实现增长，主要得益于一次性套管穿刺器、一次性电凝钳、 ...